Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad

doi:10.2337/dc06-2593

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

Tina Vilsbøll, Milan Zdravkovic, Tu Le-Thi, Thure Krarup, Ole Schmitz, Jean-Pierre Courrèges, Robert Verhoeven, Ingrid Bugánová, Sten Madsbad

455 Citations (Scopus)

Original language	English
Journal	Diabetes Care
Volume	30
Issue number	6
Pages (from-to)	1608-10
Number of pages	3
ISSN	0149-5992
DOIs	https://doi.org/10.2337/dc06-2593
Publication status	Published - 1 Jun 2007

Access to Document

10.2337/dc06-2593

Cite this

Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007). Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 30(6), 1608-10. https://doi.org/10.2337/dc06-2593

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. / Vilsbøll, Tina; Zdravkovic, Milan; Le-Thi, Tu et al.
In: Diabetes Care, Vol. 30, No. 6, 01.06.2007, p. 1608-10.

Research output: Contribution to journal › Journal article › Research › peer-review

Vilsbøll, T, Zdravkovic, M, Le-Thi, T, Krarup, T, Schmitz, O, Courrèges, J-P, Verhoeven, R, Bugánová, I & Madsbad, S 2007, 'Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes', Diabetes Care, vol. 30, no. 6, pp. 1608-10. https://doi.org/10.2337/dc06-2593

@article{ab51fed57e4a4576aff66a2f9b8601a2,

title = "Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes",

author = "Tina Vilsb{\o}ll and Milan Zdravkovic and Tu Le-Thi and Thure Krarup and Ole Schmitz and Jean-Pierre Courr{\`e}ges and Robert Verhoeven and Ingrid Bug{\'a}nov{\'a} and Sten Madsbad",

year = "2007",

month = jun,

day = "1",

doi = "10.2337/dc06-2593",

language = "English",

volume = "30",

pages = "1608--10",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "6",

}

TY - JOUR

T1 - Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

AU - Vilsbøll, Tina

AU - Zdravkovic, Milan

AU - Le-Thi, Tu

AU - Krarup, Thure

AU - Schmitz, Ole

AU - Courrèges, Jean-Pierre

AU - Verhoeven, Robert

AU - Bugánová, Ingrid

AU - Madsbad, Sten

PY - 2007/6/1

Y1 - 2007/6/1

UR - https://www.scopus.com/pages/publications/34249869806

U2 - 10.2337/dc06-2593

DO - 10.2337/dc06-2593

M3 - Journal article

C2 - 17372153

SN - 0149-5992

VL - 30

SP - 1608

EP - 1610

JO - Diabetes Care

JF - Diabetes Care

IS - 6

ER -

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

Access to Document

Other files and links

Cite this